Adam S Kittai
Overview
Explore the profile of Adam S Kittai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
323
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kittai A, Huang Y, Miller S, Allan J, Bhat S, Bond D, et al.
Blood Cancer J
. 2025 Feb;
15(1):23.
PMID: 39979241
No abstract available.
2.
Rippel N, Sheppard R, Kittai A
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796724
Richter transformation (RT) is a rare albeit devastating complication of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). RT is defined as an aggressive lymphoma, typically diffuse large B-cell lymphoma, in the...
3.
Thiruvengadam S, Merryman R, Wang Y, Gaulin C, Bezerra E, Voorhees T, et al.
Am J Hematol
. 2024 Dec;
100(2):236-248.
PMID: 39715004
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment of aggressive large B-cell lymphoma (aLBCL). Patients with transformed indolent non-Hodgkin lymphoma (tiNHL) were included in key CAR trials, but outcomes...
4.
Soumerai J, Barrientos J, Barrientos J, Ahn I, Ahn I, Coombs C, et al.
Blood Adv
. 2024 Nov;
9(5):1213-1229.
PMID: 39561376
Over the past decade, treatment recommendations for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have shifted from traditional chemoimmunotherapy to targeted therapies. Multiple new therapies are...
5.
Di Staso R, Casadei B, Locke F, Jain M, Voorhees T, Kittai A, et al.
Blood Cancer J
. 2024 Nov;
14(1):197.
PMID: 39511146
No abstract available.
6.
Lopedote P, Kittai A, Danilov A
Expert Rev Anticancer Ther
. 2024 Sep;
24(10):977-987.
PMID: 39223949
Introduction: In the era of chemo-immunotherapy, high-risk factors unequivocally predicted inferior outcomes for patients with CLL. The widespread adoption of BTK inhibitors has challenged the practical implications of such testing,...
7.
Gambril J, Ghazi S, Sansoterra S, Ferdousi M, Kola-Kehinde O, Ruz P, et al.
Leukemia
. 2024 Aug;
38(10):2141-2149.
PMID: 39154059
Bruton's tyrosine kinase inhibitors (BTKi) have dramatic efficacy against B-cell malignancies, but link with cardiotoxicity, including atrial fibrillation (AF). Burden, severity, and implications of BTKi-related AF are unknown. Leveraging a...
8.
Ravikrishnan J, Diaz-Rohena D, Muhowski E, Mo X, Lai T, Misra S, et al.
Haematologica
. 2024 Aug;
110(1):78-91.
PMID: 39113656
Patients with chronic lymphocytic leukemia (CLL) respond well to initial treatment with the B-cell lymphoma 2 (BCL2) inhibitor venetoclax. Upon relapse, they often retain sensitivity to BCL2 targeting, but durability...
9.
Denlinger N, Song N, Zhang X, Jeon H, Peterson C, Wang Y, et al.
Blood Adv
. 2024 Apr;
8(12):3140-3153.
PMID: 38607381
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Robust biomarkers and a complete understanding of CAR T-cell function in the postinfusion phase remain...
10.
Kittai A, Allan J, James D, Bridge H, Miranda M, Yong A, et al.
Blood Adv
. 2024 Apr;
8(11):2861-2869.
PMID: 38598745
The efficacy and safety of acalabrutinib plus obinutuzumab and acalabrutinib monotherapy vs zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma without del(17p) were compared using an unanchored matching-adjusted...